MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy

June 2-6, 2017; Chicago, Illinois
Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.
Format: Microsoft PowerPoint (.ppt)
File Size: 523 KB
Released: June 7, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Short downloadable slideset from Clinical Care Options (CCO) on managing HR+/HER2- early breast cancer

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: June 18, 2021

Slides from Sara Tolaney, MD, MPH, on adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: June 16, 2021

Slides from Joyce O’Shaughnessy, MD, on measures of treatment benefit for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: June 15, 2021

Slides from Sara Hurvitz, MD, FACP, on neoadjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: June 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue